The consistent OS data across geographies and the positive head-to-head HARMONi-2 data against Keytruda significantly de-risk the ivonescimab program ahead of the November PDUFA. Traders should watch for potential pre-approval investor events and any FDA advisory committee briefing documents. The stock is likely to re-rate higher as the probability of approval and peak sales estimates increase.
Drug in focus
SMMT drug pipeline →ivonescimab
◆ Mixed Named in this 8-K- Impact
- Phase
- Filed/PDUFA (BLA under FDA review); also multiple ongoing Phase 3 trials
- Time to market
- If approved, potential US launch in late 2026 or early 2027. Already approved in China (May 2024).
- Next catalyst
- None dated
What to watchThe November 14 PDUFA is the defining event. The HARMONi global trial showed statistically significant PFS but OS missed the pre-specified threshold, an unusual situation that creates binary risk on approval odds. Watch for an FDA Advisory Committee date (if scheduled) as a pre-decision signal. Also watch HARMONi-3 final PFS readout (2H 2026) as a secondary catalyst. The $500M June offering diluted existing holders but extended the cash runway, and the massive insider buying (~$100M from co-CEOs at ~$13.12) signals conviction at current levels.
How the stock moved after the report
BULLISH VIEWSTOCK BELOW ENTRY AT T+20- T+0 · Sep 15 $17.40entry
- T+1 · 2mo ago +0.80%α +0.48% · $17.54
- T+5 · 8w ago +2.59%α +1.77% · $17.85
- T+20 · 5w ago −10.80%α −13.78% · $15.52
- T+44 · todayOpen
- T+60 · in 22d Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Summit Therapeutics presented updated overall survival (OS) data from the global Phase III HARMONi trial (ivonescimab + chemo in EGFR-mutated NSCLC) and detailed OS results from the China-based HARMONi-2 trial (ivonescimab monotherapy vs. pembrolizumab) at WCLC 2026. The HARMONi data showed a consistent OS benefit with a hazard ratio of 0.76 (nominal p=0.0151) in the global ITT population, with western patients now showing a similar HR of 0.76, reinforcing the drug's profile ahead of the November 14, 2026 PDUFA date. HARMONi-2 showed a statistically significant OS benefit for ivonescimab over pembrolizumab (HR 0.73, p=0.009), further strengthening the clinical case for the asset across multiple lung cancer settings.
Key Facts
- Updated HARMONi OS HR of 0.76 (95% CI: 0.61-0.95; nominal p=0.0151) in global ITT population at June 2026 data cut-off.
- Western patient subgroup OS HR improved to 0.76 (95% CI: 0.52-1.10) with longer follow-up (median 23.2 months), matching the global trend.
- HARMONi-2 showed ivonescimab monotherapy beat pembrolizumab on OS with HR 0.73 (95% CI: 0.57-0.95; p=0.009), including a 7.6-month median OS advantage (30.8 vs 22.6 months).
- PDUFA goal date for the ivonescimab BLA in the U.S. is November 14, 2026.
- No new safety signals were observed in either HARMONi or HARMONi-2 with longer follow-up.
Financial Impact
Positive catalyst for SMMT stock; ivonescimab is the sole pipeline asset. Approval in EGFR-mutated NSCLC (HARMONi) represents a multi-billion-dollar peak sales opportunity. HARMONi-2 data supports potential label expansion into first-line PD-L1 positive NSCLC, significantly increasing the addressable market.
Risk Factors
- The HARMONi OS benefit did not reach statistical significance at the primary analysis (p=0.057), and the updated analysis uses a nominal p-value, which may be a point of FDA scrutiny.
- HARMONi-2 is a single-region China study; the FDA may require a global confirmatory trial for a first-line indication.
- Competition from other bispecific antibodies and antibody-drug conjugates in the NSCLC space is intense.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001599298-26-000081 |
| Document: a2026_prx0915xharmoniltf.htm | 0001599298-26-000081 |
| Document: 0001599298-26-000081-index-headers.html | 0001599298-26-000081 |
| Document: 0001599298-26-000081-index.html | 0001599298-26-000081 |
| Document: 0001599298-26-000081.txt | 0001599298-26-000081 |
Track record
23 reports on SMMT
6 of 11 bullish or bearish reports moved the stock their way by T+1. Best: +23.34% at T+60 after the Jun 12, 2026 report. 8 of 11 went positive at some point.
Filters
- Nov 16, 2026today 8-K Bearish 7/10 Entry $11.43 Now $11.82 −3.41% settles Nov 17
- Nov 4, 202612d ago 8-K Neutral 3/10 Entry $14.19 to $16.33 Now $11.82 −16.70% ▲ +15.08% +14.77% vs SPY
- Nov 4, 202612d ago 8-K Neutral 6/10 Entry $14.19 to $16.33 Now $11.82 −16.70% ▲ +15.08% +14.77% vs SPY
- Nov 4, 202612d ago Institutional Cluster Neutral 3/10 Entry $16.17 to $14.19 Now $11.82 −26.90% ▼ −12.24% −7.84% vs SPY
- Oct 21, 202626d ago Press Release Neutral 5/10 Entry $15.83 to $15.55 Now $11.82 −25.33% ▼ −1.77% −0.59% vs SPY
- Oct 19, 202628d ago DEF 14A Neutral 5/10 Entry $15.57 to $16.09 Now $11.82 −24.08% ▲ +3.34% +3.00% vs SPY
- Sep 28, 20267w ago 8-K Bullish 8/10 Entry $16.39 to $16.91 Now $11.82 −27.88% ▲ +3.17% +3.38% vs SPY
- Sep 15, 20268w ago 8-K Bullish 7/10 Viewing Entry $17.40 to $17.54 Now $11.82 −32.07% ▲ +0.80% +0.48% vs SPY
- Sep 14, 20269w ago 8-K Bullish 7/10 Entry $18.42 to $17.40 Now $11.82 −35.83% ▼ −5.54% −5.08% vs SPY
- Sep 3, 202610w ago 8-K Bullish 6/10 Entry $17.13 to $17.61 Now $11.82 −31.00% ▲ +2.77% +3.16% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers